Susanna High
2021
In 2021, Susanna High earned a total compensation of $1.7M as Chief Operating Officer at Dyne Therapeutics, a 55% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $221,000 |
|---|---|
| Option Awards | $528,933 |
| Salary | $425,000 |
| Stock Awards | $514,762 |
| Other | $926 |
| Total | $1,690,621 |
High received $528.9K in option awards, accounting for 31% of the total pay in 2021.
High also received $221K in non-equity incentive plan, $425K in salary, $514.8K in stock awards and $926 in other compensation.
Rankings
In 2021, Susanna High's compensation ranked 6,734th out of 12,415 executives tracked by ExecPay. In other words, High earned more than 45.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,734 out of 12,415 | 46th |
Division Manufacturing | 2,921 out of 5,505 | 47th |
Major group Chemicals And Allied Products | 1,287 out of 2,375 | 46th |
Industry group Drugs | 1,146 out of 2,096 | 45th |
Industry Pharmaceutical Preparations | 836 out of 1,546 | 46th |
Source: SEC filing on April 22, 2022.
High's colleagues
We found two more compensation records of executives who worked with Susanna High at Dyne Therapeutics in 2021.
News
Dyne Therapeutics CEO Josh Brumm's 2023 pay jumps 38% to $6M
April 5, 2024
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021